Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.
BMC Cancer. 2011 Oct 21;11:458. doi: 10.1186/1471-2407-11-458.
Hepatitis B virus (HBV) is a major cause of hepatocarcinogenesis.To identify mutations relevant to hepatocellular carcinoma (HCC) development, we compared the full genome sequences of HBV from the sera of patients with and without HCC.
We compared the full genome sequences of HBV isolates from 37 HCC patients (HCC group 1) and 38 patients without HCC (non-HCC group 1). We also investigated part of the core promoter region sequences from 40 HCC patients (HCC group 2) and 68 patients without HCC. Of the 68 patients who initially did not have HCC, 52 patients remained HCC-free during the follow-up period (non-HCC group 2), and 16 patients eventually developed HCC (pre-HCC group 2). Serum samples collected from patients were subjected to PCR, and the HBV DNA was directly sequenced.
All patients had genotype C. A comparison of the nucleotide sequences of the HBV genome between HCC group 1 and non-HCC group 1 revealed that the prevalence of G1613A and C1653T mutations in the core promoter region was significantly higher in the HCC group. These mutations tended to occur simultaneously in HCC patients. Multivariate analysis with group 2 revealed that the presence of HCC was associated with aging and the double mutation. Future emergence of HCC was associated with aging and the presence of a single G1613A mutation.
G1613A and C1653T double mutations were frequently found in patients with HCC. A single G1613A mutation was associated with future emergence of HCC. These mutations may serve as useful markers in predicting HCC development.
乙型肝炎病毒(HBV)是导致肝癌发生的主要原因。为了确定与肝细胞癌(HCC)发展相关的突变,我们比较了来自有 HCC 和无 HCC 患者血清中的 HBV 全基因组序列。
我们比较了 37 例 HCC 患者(HCC 组 1)和 38 例无 HCC 患者(非 HCC 组 1)的 HBV 全基因组序列。我们还研究了 40 例 HCC 患者(HCC 组 2)和 68 例无 HCC 患者的核心启动子区序列的一部分。在最初没有 HCC 的 68 例患者中,有 52 例在随访期间保持无 HCC(非 HCC 组 2),16 例最终发展为 HCC(前 HCC 组 2)。采集患者的血清样本进行 PCR,直接对 HBV DNA 进行测序。
所有患者均为基因型 C。HCC 组 1 与非 HCC 组 1 之间 HBV 基因组核苷酸序列的比较表明,核心启动子区 G1613A 和 C1653T 突变的发生率在 HCC 组中明显更高。这些突变在 HCC 患者中往往同时发生。对组 2 的多变量分析显示,存在 HCC 与年龄和双突变有关。未来出现 HCC 与年龄和单个 G1613A 突变的存在有关。
G1613A 和 C1653T 双突变在 HCC 患者中经常发现。单个 G1613A 突变与未来 HCC 的发生有关。这些突变可能成为预测 HCC 发展的有用标志物。